PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
14718589-1	2004	The 2-phenylaminopyrimidine derivative imatinib-mesylate, a powerful protein tyrosine kinase (PTK) inhibitor that targets abl, c-kit, and the platelet-derived growth factor receptors, is rapidly gaining a relevant role in the treatment of several types of neoplasms.	N-phenylpyrimidin-2-amine	4-27	KIT proto-oncogene, receptor tyrosine kinase	Homo sapiens	127-132	
11495816-4	2001	Produced from the 2-phenylaminopyrimidine class, a novel synthetic inhibitor, identified as CGP57148 (STI571), inhibits tyrosine kinase activity of c-ABL, BCR-ABL, PDGF-R and c-kit at micromolar concentrations.	N-phenylpyrimidin-2-amine	18-41	KIT proto-oncogene, receptor tyrosine kinase	Homo sapiens	175-180	
11342454-1	2001	The 2-phenylaminopyrimidine derivative STI571 is a selective inhibitor of c-Abl, c-kit, and platelet-derived growth factor-receptor tyrosine kinases and is presently in phase II-III clinical studies.	N-phenylpyrimidin-2-amine	4-27	KIT proto-oncogene, receptor tyrosine kinase	Homo sapiens	81-86